<DOC>
	<DOCNO>NCT01869686</DOCNO>
	<brief_summary>This phase 1b , open-label , single dose study healthy male subject . Approximately 12 healthy male subject receive subcutaneous injection denosumab Day 1 . Subjects follow 105 day treatment-free follow-up period .</brief_summary>
	<brief_title>Study Evaluate Concentration Denosumab Seminal Fluid Healthy Men After Single Subcutaneous Dose</brief_title>
	<detailed_description />
	<mesh_term>Denosumab</mesh_term>
	<criteria>Subject provide informed consent ; Healthy male ≥40 ≤ 65 year age ( inclusive ) time enrollment ; Subject must willing able produce semen sample seven separate study visit ; Subject must willing refrain ejaculation 48 hour period prior sample collection ; Any condition drug therapy might interfere subject ability ejaculate produce semen sample ; Clinically significant abnormality screen physical examination , ECG , laboratory evaluation ; Known history blood urine semen ; Osteonecrosis jaw ( ONJ ) risk factor ONJ invasive dental procedure ( eg , tooth extraction , dental implant , oral surgery past 6 month ) , poor oral hygiene , periodontal and/or preexist dental disease ; Recent tooth extraction ( within 6 month screen visit ) ; Evidence hypocalcemia screening ; Known vitamin D deficiency ; Malignancy ( except nonmelanoma skin cancer ) within last 5 year ; Positive human immunodeficiency virus ( HIV ) screen know diagnosis AIDS ; Positive Hepatitis B Surface Antigen ( HepBsAg ) ( indicative chronic Hepatitis B ) detectable Hepatitis C virus Ribonucleic acid ( RNA ) Polymerase Chain Reaction ( PCR ) screening ( indicative active Hepatitis C screen generally do Hepatitis C Antibody ( HepCAb ) , follow Hepatitis C virus RNA PCR HepCAb positive ) ; History hypersensitivity allergic reaction mammalian cell derive drug product sensitivity product component administer dose ; Known intolerance calcium vitamin D supplement ; Subject previously enter study previously expose denosumab past 12 month ; Has donate lose ≥ 400 mL blood plasma within 8 week prior screen ; Positive urine screen alcohol and/or potential drug abuse screen unless medication prescribe physician approve Investigator Amgen ; Known alcohol abuse use illicit drug within 12 month enrollment ; Subject unwilling unable limit alcohol consumption throughout course study . Alcohol prohibit 24 hour prior screen administration investigational product . Alcohol limit 2 drink per day duration study ; standard drink equivalent 12 ounce regular beer , 89 ounce malt liquor , 5 ounce wine , 1.5 ounce 80 proof distilled spirit ; Currently receive treatment another investigational device drug study , less 30 day 5 halflives ( whichever longer ) since end treatment another investigational device drug study ( ) . Other investigational procedure participate study exclude ; Use nonAmgen approve overthecounter prescription medication , within 14 day 5 halflives ( whichever longer ) , prior receive dose denosumab . Acetaminophen ( 2 g per day ) analgesia hormone replacement therapy ( eg , androgen , thyroid ) allow . Other medication may approve follow review Principal Investigator Amgen Medical Monitor . Written documentation review Amgen acknowledgement require subject participation ; Subject likely available complete protocolrequired study visit procedure , and/or comply require study procedure best subject Investigator 's knowledge ; Subject kind disorder , opinion Investigator , may compromise ability subject give write informed consent and/or comply require study procedure ; History evidence clinically significant disorder , condition disease , opinion Investigator Amgen physician , consult , would pose risk subject safety interfere study evaluation , procedure completion</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>